• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Weighing the risk of drug resistance with the benefits of HIV preexposure prophylaxis.

作者信息

Grant Robert M, Liegler Teri

机构信息

Gladstone Institutes University of California-San Francisco San Francisco AIDS Foundation, California.

University of California-San Francisco.

出版信息

J Infect Dis. 2015 Apr 15;211(8):1202-4. doi: 10.1093/infdis/jiu678. Epub 2015 Jan 13.

DOI:10.1093/infdis/jiu678
PMID:25587019
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4371769/
Abstract
摘要

相似文献

1
Weighing the risk of drug resistance with the benefits of HIV preexposure prophylaxis.权衡HIV暴露前预防的益处与耐药风险。
J Infect Dis. 2015 Apr 15;211(8):1202-4. doi: 10.1093/infdis/jiu678. Epub 2015 Jan 13.
2
[Pre-exposure prophylaxis and selection of HIV resistant strains: Attention should be paid to the pre-exposure prophylaxis initiated during the seronegative initial period of HIV primary infection ].暴露前预防与HIV耐药毒株的选择：应关注在HIV初次感染血清阴性初期启动的暴露前预防。
Med Mal Infect. 2015 Aug;45(8):341-2. doi: 10.1016/j.medmal.2015.06.004. Epub 2015 Aug 8.
3
Update on antiretroviral treatment during primary HIV infection.原发性 HIV 感染期间的抗逆转录病毒治疗进展。
Expert Rev Anti Infect Ther. 2014 Jul;12(7):793-807. doi: 10.1586/14787210.2014.913981. Epub 2014 May 7.
4
Resistance to antiretroviral drugs: a threat to the prevention and treatment of pediatric HIV infection.对抗逆转录病毒药物的耐药性：对儿童HIV感染预防和治疗的威胁。
J Infect Dis. 2007 May 15;195(10):1393-5. doi: 10.1086/513880. Epub 2007 Apr 5.
5
Antiretroviral resistance in clinical practice.临床实践中的抗逆转录病毒耐药性。
J Int Assoc Physicians AIDS Care (Chic). 2003 Sep;2 Suppl 1:S4-18.
6
Development of antiretroviral drug resistance.抗逆转录病毒药物耐药性的发展。
N Engl J Med. 2011 Aug 18;365(7):637-46. doi: 10.1056/NEJMra1004180.
7
Antiretroviral drug resistance and resistance testing.抗逆转录病毒药物耐药性及耐药性检测
Top HIV Med. 2005;13(5):138-42.
8
Continued correspondence 'Will ART rollout in Africa drive an epidemic of drug-resistant HIV?'.持续通信：“非洲抗逆转录病毒疗法的推广会引发耐药性艾滋病毒的流行吗？”
AIDS. 2007 Jan 11;21(2):258-9; author reply 259-60. doi: 10.1097/QAD.0b013e32801121fb.
9
[Determination of serum levels of antiretroviral drugs].[抗逆转录病毒药物血清水平的测定]
MMW Fortschr Med. 2004 Apr 26;146 Spec No 1:62-4.
10
Resistance to HIV drugs in UK may be lower in some areas.在英国，某些地区对艾滋病病毒药物的耐药性可能较低。
BMJ. 2006 Jan 21;332(7534):179-80. doi: 10.1136/bmj.332.7534.179-c.

引用本文的文献

1
Clinical Presentation, Treatment Response, and Virology Outcomes of Women Who Seroconverted in the Dapivirine Vaginal Ring Trials-The Ring Study and DREAM.在 dapivirine 阴道环试验（Ring 研究和 DREAM）中血清转换的女性的临床表现、治疗反应和病毒学结局。
Clin Infect Dis. 2023 Feb 8;76(3):389-397. doi: 10.1093/cid/ciac804.
2
Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring.在 Microbicide Trials Network-020 三期临床试验中，接受地蒽诺辛阴道环治疗的血清转换者开始抗逆转录病毒治疗的临床和病毒学结局。
Clin Infect Dis. 2019 Jul 18;69(3):523-529. doi: 10.1093/cid/ciy909.
3
HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial.在一项基于替诺福韦的HIV预防试验中，女性血清转化后的HIV疾病进展情况。
PLoS One. 2017 Jun 28;12(6):e0178594. doi: 10.1371/journal.pone.0178594. eCollection 2017.
4
Pre-Exposure Prophylaxis: A Narrative Review of Provider Behavior and Interventions to Increase PrEP Implementation in Primary Care.暴露前预防：关于医疗服务提供者行为及增加初级保健中暴露前预防实施率的干预措施的叙述性综述
J Gen Intern Med. 2017 Feb;32(2):192-198. doi: 10.1007/s11606-016-3899-4. Epub 2016 Oct 19.
5
How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact.我们对因使用暴露前预防（PrEP）导致的耐药性了解多少？专家意见分析及其对预计公共卫生影响的作用
PLoS One. 2016 Jul 8;11(7):e0158620. doi: 10.1371/journal.pone.0158620. eCollection 2016.
6
Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa.撒哈拉以南非洲地区孕期及哺乳期艾滋病病毒暴露前预防的成本效益
J Acquir Immune Defic Syndr. 2016 Aug 1;72 Suppl 2(Suppl 2):S145-53. doi: 10.1097/QAI.0000000000001063.
7
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations.针对所有人群的口服HIV暴露前预防的有效性和安全性。
AIDS. 2016 Jul 31;30(12):1973-83. doi: 10.1097/QAD.0000000000001145.
8
Integrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early Treatment.整合抗逆转录病毒策略预防人类免疫缺陷病毒：暴露前和暴露后预防以及早期治疗。
Open Forum Infect Dis. 2015 Aug 26;2(4):ofv126. doi: 10.1093/ofid/ofv126. eCollection 2015 Dec.
9
The current status of the use of oral medication to prevent HIV transmission.口服药物预防HIV传播的应用现状。
Curr Opin HIV AIDS. 2015 Jul;10(4):226-32. doi: 10.1097/COH.0000000000000170.

本文引用的文献

1
Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.在单药或双药暴露前预防的随机临床试验中感染艾滋病毒者的耐药风险。
J Infect Dis. 2015 Apr 15;211(8):1211-8. doi: 10.1093/infdis/jiu677. Epub 2015 Jan 13.
2
Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.单药替诺福韦与恩曲他滨联合替诺福韦用于HIV-1暴露前预防：一项随机、双盲、3期试验数据的更新
Lancet Infect Dis. 2014 Nov;14(11):1055-1064. doi: 10.1016/S1473-3099(14)70937-5. Epub 2014 Oct 7.
3
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.男男性行为者和男变女性别者中暴露前预防措施的采用情况、性行为及艾滋病毒发病率：一项队列研究
Lancet Infect Dis. 2014 Sep;14(9):820-9. doi: 10.1016/S1473-3099(14)70847-3. Epub 2014 Jul 22.
4
Single-pill combination regimens for treatment of HIV-1 infection.用于治疗HIV-1感染的单片复方治疗方案。
N Engl J Med. 2014 Jul 17;371(3):248-59. doi: 10.1056/NEJMct1215532.
5
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.在一项用于预防 HIV 的 PrEP 临床试验中，替诺福韦的血液浓度与 HIV 保护效果及相关因素。
J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):340-8. doi: 10.1097/QAI.0000000000000172.
6
HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.在iPrEx暴露前预防试验中的HIV-1耐药性
J Infect Dis. 2014 Oct 15;210(8):1217-27. doi: 10.1093/infdis/jiu233. Epub 2014 Apr 16.
7
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.在曼谷泰国注射吸毒者中预防艾滋病毒感染的抗逆转录病毒预防（曼谷替诺福韦研究）：一项随机、双盲、安慰剂对照的 3 期临床试验。
Lancet. 2013 Jun 15;381(9883):2083-90. doi: 10.1016/S0140-6736(13)61127-7. Epub 2013 Jun 13.
8
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.接受暴露前预防（PrEP）的男男性行为者的恩曲他滨替诺福韦浓度与预防效果。
Sci Transl Med. 2012 Sep 12;4(151):151ra125. doi: 10.1126/scitranslmed.3004006.
9
Preexposure prophylaxis for HIV infection among African women.预防非洲女性感染 HIV 的暴露前预防措施。
N Engl J Med. 2012 Aug 2;367(5):411-22. doi: 10.1056/NEJMoa1202614. Epub 2012 Jul 11.
10
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.博茨瓦纳异性传播 HIV 中抗逆转录病毒的预先暴露预防。
N Engl J Med. 2012 Aug 2;367(5):423-34. doi: 10.1056/NEJMoa1110711. Epub 2012 Jul 11.